[1] |
Ilic M,Ilic I. Epidemiology of pancreatic cancer[J]. World J Gastroenterol,2016,22(44):9694-9705.
|
[2] |
Vincent A,Herman J,Schulick R,et al. Pancreatic cancer[J]. Lancet,2011,378(9791):607-620.
|
[3] |
赵建国,廖泉,赵玉沛. 胰腺癌分子标志物研究进展[J/CD]. 中华普外科手术学杂志(电子版),2013,7(03):224-226.
|
[4] |
Huang J,Liu J,Chen-Xiao K,et al. Advance in microRNA as a potential biomarker for early detection of pancreatic cancer[J]. Biomark Res,2016,4:20.
|
[5] |
Chandra Gupta S,Nandan Tripathi Y. Potential of long non-coding RNAs in cancer patients:From biomarkers to therapeutic targets[J]. Int J Cancer,2017,140(9):1955-1967.
|
[6] |
谢雨婷,高军. 微小RNA在胰腺癌诊断中的研究进展[J]. 中华胰腺病杂志,2022,22(02):148-152.
|
[7] |
Schultz NA,Dehlendorff C,Jensen BV,et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer[J]. JAMA,2014,311(4):392-404.
|
[8] |
Chen J,Yao D,Chen W,et al. Serum exosomal miR-451a acts as a candidate marker for pancreatic cancer[J]. Int J Biol Markers,2022,37(1):74-80.
|
[9] |
Yang J,Xu R,Wang C,et al. Early screening and diagnosis strategies of pancreatic cancer:a comprehensive review[J]. Cancer Commun(Lond),2021,41(12):1257-1274.
|
[10] |
Szafranska-Schwarzbacht AE,Adai AT,Lee LS,et al. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma[J]. Expert Rev Mol Diagn,2011,11(3):249-257.
|
[11] |
Morimura R,Komatsu S,Ichikawa D,et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer[J]. Br J Cancer,2011,105(11):1733-1740.
|
[12] |
Kawaguchi T,Komatsu S,Ichikawa D,et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer[J]. Br J Cancer,2013,108(2):361-369.
|
[13] |
Liang L,Wei DM,Li JJ,et al. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer:A study based on The Cancer Genome Atlas and bioinformatics investigation[J]. Mol Med Rep,2018,17(1):939-951.
|
[14] |
Muro K,Fuchs CS,Jang RWJ,et al. KEYNOTE-059 cohort 1:Pembrolizumab(Pembro)monotherapy in previously treated advanced gastric or gastroesophageal junction(G/GEJ)cancer in patients(Pts)with PD-L1+tumors-Asian subgroup analysis[J]. J Clinical Onc,2018,36(4):1.
|
[15] |
Wang P,Zhuang L,Zhang J,et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer,and miR-21 expression confers chemoresistance by targeting FasL[J]. Mol Oncol,2013,7(3):334-345.
|
[16] |
Gisel A,Valvano M,El Idrissi IG,et al. miRNAs for the Detection of MultiDrug Resistance:Overview and Perspectives[J]. Molecules 2014,19(5):5611-5623.
|
[17] |
Jung H,Ertl L,Janson C,et al. Inhibition of CCR2 potentiates the checkpoint inhibitor immunotherapy in pancreatic cancer[J]. Cancer Immunol Res,2016,4(11):1123.
|
[18] |
Lu Y,Lu J,Li X,et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell[J]. BMC Cancer,2014,14:85.
|
[19] |
Ma C,Huang T,Ding YC,et al. microRNA-200c overexpression inhibits chemoresistance,invasion and colony formation of human pancreatic cancer stem cells[J]. Int J Clin Exp Pathol,2015,8(6):6533-6539.
|
[20] |
Singh S,Chitkara D,Kumar V,et al. miRNA profiling in pancreatic cancer and restoration of chemosensitivity[J]. Cancer Lett,2013,334(2):211-220.
|
[21] |
Mittal A,Chitkara D,Behrman SW,et al. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer[J]. Biomaterials,2014,35(25):7077-7087.
|
[22] |
Sicard F,Gayral M,Lulka H,et al. Targeting miR-21 for the Therapy of Pancreatic Cancer[J]. Mol Ther,2013,21(5):986-994.
|
[23] |
Huarte M. The emerging role of lncRNAs in cancer[J]. Nat Med,2015,21(11):1253-1261.
|
[24] |
Wang Y,Li Z,Zheng S,et al. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers[J]. Oncotarget,2015,6(34):35684-35698.
|
[25] |
Li L,Zhang GQ,Chen H,et al. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer[J]. Oncotarget,2016,7(44):71773-71781.
|
[26] |
Lu H,Yang D,Zhang L,et al. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-beta pathway activation[J]. Oncol Lett,2019,17(5):4633-4639.
|
[27] |
Liu Y,Feng W,Liu W,et al. Circulating lncRNA ABHD11-AS1 serves as a biomarker for early pancreatic cancer diagnosis[J]. J Cancer,2019,10(16):3746-3756.
|
[28] |
Lu H,Ye J,Zhang L,et al. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF-beta signaling[J]. Mol Med Rep,2019,20(5):4533-4539.
|
[29] |
Takahashi K,Ota Y,Kogure T,et al. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer[J]. Cancer Sci,2020,111(1):98-111.
|
[30] |
Pan S,Shen M,Zhou M,et al. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924[J]. Cell Death Dis,2019,10(12):883.
|
[31] |
Li Z,Zhao X,Zhou Y,et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer[J]. J Transl Med,2015,13:84.
|
[32] |
You L,Wang H,Yang G,et al. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207[J]. Mol Oncol,2018,12(12):2147-2164.
|
[33] |
Gonzalez-Duarte A,Berk JL,Quan D,et al. Analysis of autonomic outcomes in APOLLO,a phase Ⅲ trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis[J]. J Neurol,2020,267(3):703-712.
|
[34] |
Zhen S,Li X. Application of CRISPR-Cas9 for Long Noncoding RNA Genes in Cancer Research[J]. Hum Gene Ther,2019,30(1):3-9.
|
[35] |
Yang F,Liu DY,Guo JT,et al. Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer[J]. World J Gastroenterol,2017,23(47):8345-8354.
|
[36] |
Xu Y,Yao Y,Gao P,et al. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294[J]. Biochem Biophys Res Commun,2019,509(1):138-142.
|
[37] |
Hao L,Rong W,Bai L,et al. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation,apoptosis,and invasion by sponging miR-625 and miR-892b[J]. J Cell Biochem,2019,120(3):3780-3789.
|
[38] |
Xu C,Yu Y,Ding F. Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells[J]. Oncol Rep,2018,40(1):395-404.
|
[39] |
Liu Y,Xia L,Dong L,et al. CircHIPK3 Promotes Gemcitabine(GEM)Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1[J]. Cancer Manag Res,2020,12:921-929.
|